Stay updated on Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.

Latest updates to the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedRevision: v3.5.2 is now displayed on the page, replacing the previous v3.5.0.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedUpdated two location entries from Napoli, Italy, 80131 and 87100 to Naples, Italy, 80131 and 87100.SummaryDifference0.1%

- Check39 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check68 days agoChange DetectedFallopian tube cancer was added to the eligible conditions in the study description. The study now targets FRα-expressing tumors across ovarian, primary peritoneal, and fallopian tube cancers.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision: v3.4.2 has been added to the site. The previous Revision: v3.4.1 entry and the outdated government operating-status notice were removed; no changes to the study content.SummaryDifference0.2%

Stay in the know with updates to Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Folate Receptor-Alpha Cancer Clinical Trial page.